Cargando…
Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.
Secretory leucocyte protease inhibitor (SLPI) is a potent inhibitor of granulocyte elastase and cathepsin G, and also an inhibitor of pancreatic enzymes like trypsin, chymotrypsin and pancreatic elastase. SLPI has also been shown to inhibit HIV-1 infections by blocking viral DNA synthesis. Since SLP...
Autores principales: | Nyström, M, Bergenfeldt, M, Ljungcrantz, I, Lindeheim, A, Ohlsson, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781797/ https://www.ncbi.nlm.nih.gov/pubmed/10704052 |
Ejemplares similares
-
The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation.
por: Westin, U, et al.
Publicado: (2002) -
Novel distribution of the secretory leucocyte proteinase inhibitor in kidney.
por: Ohlsson, S, et al.
Publicado: (2001) -
Increased Secretory Leukocyte Protease Inhibitor (SLPI) Production by Highly Metastatic Mouse Breast Cancer Cells
por: Sayers, Kevin T., et al.
Publicado: (2014) -
Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
por: Dickey, Brittney L., et al.
Publicado: (2021) -
IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release.
por: Westin, U, et al.
Publicado: (1998)